Last reviewed · How we verify
Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Onoact | LANDIOLOL | Aop Hlth Us | landiolol | Beta-1 adrenergic receptor | 2024-01-01 | |
| Bretylium Tosylate | BRETYLIUM | Pfizer | bretylium | Beta-1 adrenergic receptor | 1986-01-01 | |
| Cordarone | AMIODARONE | Pfizer | Antiarrhythmic | sodium channels, potassium channels, calcium channels | 1985-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Ventricular Fibrillation
- Aop Hlth Us · 1 drug in Ventricular Fibrillation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Ventricular Fibrillation:
- Ventricular Fibrillation treatment updates — RSS
- Ventricular Fibrillation treatment updates — Atom
- Ventricular Fibrillation treatment updates — JSON
Cite this brief
Drug Landscape (2026). Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ventricular-fibrillation. Accessed 2026-06-10.
Related
- Ventricular Fibrillation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing